(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA ® (talazoparib ...
5hon MSN
Hydrogen production from seawater: Low-cost catalyst could cut energy use and resist corrosion
Using a range of advanced characterization techniques, researchers say they have developed a novel method with the potential ...
A new review argues that mTOR's effects in atherosclerotic plaques depend on cell state, plaque niche, signalling complex and ...
Nutritional modulation of gut microbiota must account for a complex web of factors, including age, genetics, lifestyle, ...
A network-pharmacology study identifies candidate gut microbial metabolites and six core targets that may help explain immune ...
The approval makes the PARP inhibitor available earlier in the line of treatment for some patients with metastatic disease.
Commercial buildings rarely maintain the same cooling demand throughout an entire day”— Jennifer Lingo BATON ROUGE, LA, ...
Primary safety endpoint achieved; exploratory findings highlight encouraging survival outcomes in heavily pretreated ...
1. FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer ...
Corcept Therapeutics surged 5.9% Monday to $90.92 after reporting positive Phase 2 data for its ovarian cancer treatment ...
The FDA previously approved FoundationOne CDx, which uses a tumor tissue sample, and FoundationOne Liquid CDx, which uses a ...
Cardiac contractility modulation therapy continued to reduce heart failure hospitalizations and improved functional class and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results